Sector News

Hostile Sanofi puts forth its slate of Medivation directors

May 26, 2016
Life sciences

Sanofi is powering through with its hostile takeover attempt for Medivation–and as it does, even more potential suitors may be weighing an entry into the fray.

Wednesday, the French pharma giant put forth a slate of 8 candidates to replace the California drugmaker’s entire board–a move it had “no choice” but to make, given Medivation’s rejection of Sanofi’s $9.3 billion offer and refusal to come to the bargaining table, CEO Olivier Brandicourt said in a statement.

Sanofi’s board nominees–Michael Campbell, Barbara Deptula, Wendy Lane, Ronald Rolfe, Steven Shulman, Charles Slacik, James Tyree and David Wilson–boast experience in pharma, finance and law, and the way the company sees it, their openness to a potential deal makes them “more open to supporting the best interests of Medivation shareholders.”

Sanofi, eager to add Medivation prostate cancer phenom Xtandi to an oncology portfolio that needs a boost, has been pursuing Medivation for months now, despite getting the cold shoulder. The San Francisco company urged its shareholders Wednesday to reject Sanofi’s attempt at a board overhaul, reiterating its opinion that the Big Pharma’s $52.50-per-share offer “substantially undervalues” it.

Meanwhile, though, other interested parties have begun lining up–and they haven’t all met with the same chilly reception. Earlier this month, Reuters reported that Medivation had opened its books up to wannabe buyers including Pfizer and Amgen–a play Sanofi was none too happy about.

“There have been published reports that you have signed confidentiality agreements with other parties. If that is accurate, we cannot see how you have not done so with us,” Brandicourt wrote in a letter to Medivation’s board.

Unfortunately for Sanofi, the line to talk takeover with Medivation may be getting longer instead of shorter. Biotech heavyweights Celgene and Gilead are now considering making their own bids for the company, Bloomberg reported Wednesday; they join a list of rumored suitors that already includes Pfizer, Amgen, Novartis and AstraZeneca.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 3, 2022

Sanofi moves into swanky new Paris HQ designed around hybrid work and sustainability

Life sciences

Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.

December 3, 2022

As CEO Schultz eyes retirement, Teva taps former Sandoz head Francis as its next leader

Life sciences

On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.

December 3, 2022

General Electric sets healthcare division spinoff plans

Life sciences

General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.